Literature DB >> 17983927

Immunosuppressive agents: effects on glucose and lipid metabolism.

Savitha Subramanian1, Dace L Trence.   

Abstract

Immunosuppressive therapies are critical elements in successful organ transplantation. Although immunosuppressant drugs are essential in preventing graft rejection and graft maintenance after transplantation, their use is complicated by adverse effects, many being detrimental to graft and even patient long-term survival. Commonly used agents are associated with dysregulated glucose metabolism and dyslipidemia. This article focuses on the effects of immunosuppressive agents on glucose and lipid metabolism. Adrenal effects of these drugs, where known, also are discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17983927     DOI: 10.1016/j.ecl.2007.07.003

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  18 in total

Review 1.  Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation.

Authors:  Alberto Baroja-Mazo; Beatriz Revilla-Nuin; Pablo Ramírez; José A Pons
Journal:  World J Transplant       Date:  2016-03-24

2.  Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.

Authors:  Jiu-Lin Song; Wei Gao; Yan Zhong; Lu-Nan Yan; Jia-Yin Yang; Tian-Fu Wen; Bo Li; Wen-Tao Wang; Hong Wu; Ming-Qing Xu; Zhe-Yu Chen; Yong-Gang Wei; Li Jiang; Jian Yang
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

Review 3.  Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients.

Authors:  Bernard Lawrence Marini; Sung Won Choi; Craig Alan Byersdorfer; Simon Cronin; David G Frame
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-20       Impact factor: 5.742

4.  Pediatric kidney transplantation using a novel protocol of rapid (6-day) discontinuation of prednisone: 2-year results.

Authors:  Blanche M Chavers; Y Catherine Chang; Kristen J Gillingham; Arthur Matas
Journal:  Transplantation       Date:  2009-07-27       Impact factor: 4.939

5.  Improved human islet preparations using glucocorticoid and exendin-4.

Authors:  Atsushi Miki; Camillo Ricordi; Toshiyuki Yamamoto; Yasunaru Sakuma; Ryosuke Misawa; Atsuyoshi Mita; Luca Inverardi; Rodolfo Alejandro; Hirohito Ichii
Journal:  Pancreas       Date:  2014-11       Impact factor: 3.327

6.  Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events.

Authors:  Kymberly D Watt; Chun Fan; Terry Therneau; Julie K Heimbach; Eric C Seaberg; Michael R Charlton
Journal:  Liver Transpl       Date:  2014-05-26       Impact factor: 5.799

7.  New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Vera Dalla Via; JÖrg P Halter; Sabine Gerull; Christian Arranto; AndrÉ Tichelli; Dominik Heim; Jakob R Passweg; Michael Medinger; Nicole Cesana-Nigro
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

8.  Evolution of β-Cell Replacement Therapy in Diabetes Mellitus: Islet Cell Transplantation.

Authors:  Cyrus Jahansouz; Cameron Jahansouz; Sean C Kumer; Kenneth L Brayman
Journal:  J Transplant       Date:  2011-10-15

Review 9.  The role of everolimus in liver transplantation.

Authors:  Rainer Ganschow; Jörg-Matthias Pollok; Martin Jankofsky; Guido Junge
Journal:  Clin Exp Gastroenterol       Date:  2014-09-02

Review 10.  Tolerance in liver transplantation: Biomarkers and clinical relevance.

Authors:  Alberto Baroja-Mazo; Beatriz Revilla-Nuin; Pascual Parrilla; Laura Martínez-Alarcón; Pablo Ramírez; José Antonio Pons
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.